8Gao Q, Jiang Y, Ma T, et al. A critical function of Thl7pFoinflammatory cells in the development of atherosclerotic plaquein mice. The Journal of Immunology, 2010, 185 : 5820-5827.
9van Es T, van Puijvelde GH, Ramos OH, et al. Attenuatedatherosclerosis upon IL-17R signaling disruption in LDLr deficientmice. Biochem Biophys Res Commun, 2009, 388:261-265.
10Smith E, Prasad KM, Butcher M, et al. Blockade of IL-17 Aresults in reduced atherosclerosis in apoE-deficient mice.Circulation, 2010, 121:1746-1755.
二级参考文献88
1Bettelli E, Korn T, Kuchroo VK. Th17: the third membet of the effector T cell trilogy[J]. Curr Opin Immunol, 2007,19:652-657.
2Veldhoen M, Hocking RJ, Atkins C J, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J]. Immunity, 2006,24:179-189.
3Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J]. Nature, 2006,441:235- 238.
4GaffenSL, KramerJM, YuJJ, etal. The IL-17 cytokine family[J]. Vitam Horm, 2006,74:255-282.
5Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis[J]. J Immunol, 2006,177:566-573.
6Hata K, Andoh A, Shimada M, et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts[J]. Am J Physiol Gastrointest Liver Physiol, 2002,282 :G1035-1044.
7Reinhardt RL, Kang SJ, Liang HE, etal. T helper cell effector fates-who, how and where[J]? Curr Opin Immunol, 2006, 18:271-277.
8Wraith DC, Nicolson KS, Whitley NT. Regulatory CD4^+ T cells and the control of autoimmune disease[J]. Curr Opin Immunol, 2004, 16:695-701.
9Langrish CI., Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmuneinflammation[J]. J Exp Med, 2005,201:233-240.
10Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17^+ T helper cells[J]. Cell, 2006, 126:1121-1133.
3Hashmi S,Zeng QT.Role of interleukin-17 andinterleukin-17-induced cytokines interleukin-6 andinterleukin-8 in unstable coronary artery disease[J].Coron Artery Dis,2006,17:699-706.
4deBoer OJ,van der Meer JJ,Teeling P,et al.Differential expression of interleukin-17 familycytokines in intact and complicated humanatherosclerotic plaques[J].Pathol,2010,220:499-508.
5Raymond EE,Deepak AR,Zhou J,et al.Interleukin-17 and interferon-gamma are producedconcomitantly by human coronary artery-infiltratingT cells and act synergistically on vascular smoothmuscle cells[J].Circulation,2009,119:1424-1432.
6Simon T,Taleb S,Danchin N,et al.Circulatinglevels of interleukin-17 and cardiovascular outcomesin patients with acute myocardial infarction[J].EurHeart J,2013,34:570-577.
7Zhang X,Jin J,Peng X,et al.Simvastatin inhibitsIL-17 secretion by targeting multiple IL-17-regulatorycytokines and by inhibiting the expression of IL-17transcription factor RORC in CD4+ lymphocytes[J].J Immunol?2008 ?180:6988-6996.
